Phaseline

Targets › CSFR3

CSFR3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Oct 2027.

Open in Phaseline: the race on CSFR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Henan Cancer HospitalEfbemalenograstim alfa
Granulocyte colony-stimulating factor (G-CSF) receptor agonist
CSFR3Phase 2Primary/Secondary PreventionOct 2027

Conditions

Primary/Secondary Prevention (1)

Modalities

protein or peptide (1)

Companies

Henan Cancer Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.